Death Clock adds AI-powered blood biomarker anal
Author: Michael
As psychedelics emerge as tools for cognitive re
Big pharma AstraZeneca partners with Hong Kong’s CSPC to develop next-gen weight management drugs worldwide. Managing your weight is possible without complicated schedules, multiple pills or daily injections. That’s the vision British-Swedish pharma giant AstraZeneca is chasing with its latest move: a massive $18.5 billion licensing deal with Hong Kong-based CSPC Pharmaceutical Group to develop and commercialize cutting-edge obesity drugs outside China, Hong Kong, Macao and Taiwan [1]. The core of the deal is SYH2082, an injectable drug candidate that’s ready for clinical trials, along with several other programs designed to make weight loss more consistent, effective and patient-friendly. AstraZeneca…
First patient dosing signals growing confidence
Pre-seed funding will help Xella build tools tha
From peptides to stem cells, a physician shows h
Preclinical results spotlight a new AI-driven ap
New research maps the slow cascade from brief ta
Company initially targets ‘exosome-based welln
Drug could offer weekly at-home injections, simp